manufacturing
| 4 min read
Enzymatic ligation may cut synthesis waste by nearly an order of magnitude, and Agilent's Boulder lab now puts that potential to a manufacturing test
| 4 min read
Transgene expands a duck-cell-line license as its personalized cancer vaccines advance deeper into the clinic
| 5 min read
The science behind personalized mRNA cancer vaccines is working. Building a different drug for every patient, at scale, is the real fight.
| 3 min read
Beyond mRNA vaccines, siRNA and antisense therapies are advancing as chemistry, AI, and manufacturing finally keep pace with clinical ambition.
| 4 min read
A cascade of high-profile drug recalls and evolving FDA and EMA guidance have pushed nitrosamine risk assessment from a late-stage afterthought to an early-development priority
| 5 min read
Aurion Biotech's manufacturing approach to unmodified allogeneic corneal endothelial cells offers a set of hard-won lessons for a cell therapy field still working out how to get from proof-of-concept to broad patient access.
| 5 min read
The Synthetic Molecule Process Innovation Phorum brings together major pharma companies, regulators, and CDMOs to build consensus on pressing challenges in small molecule manufacturing.
| 5 min read
The field's foundational biology is no longer the limiting factor. What comes next depends on whether the industry can build the manufacturing, commercial, and clinical infrastructure to match what the science already knows how to do.
Page 1 of 1 - 8 Total Items
